Experts say “COVID toe” is a condition similar to skin damage from exposure to low temperatures.
Northwestern Medicine dermatologist Dr. Amy Paller said in a statement that she had seen images of about 30 cases of the condition. She emphasized that it’s still unknown whether this is related to COVID-19 and more testing is needed.
“We’re seeing this inflammatory response that we would normally see when someone was exposed to the cold temperature… like someone who has been playing outside with wet socks,” Dr. Esther Freeman, a dermatologist at Massachusetts General Hospital in Boston, told CBS News. “However, in this setting, we’re seeing it in warm climates and we’re seeing it in patients who have been indoors and sheltering in place.”
Beginning as a “pinkish-reddish rash,” it can turn purple over time and causes a burning sensation in some people, Freeman told The Washington Post.
However, the inflammation typically disappears without treatment in 2 to 3 weeks, she added.
Los Angeles Mayor Eric Garcetti said the city will offer free tests for COVID-19 to all residents who want one. People don’t need to have symptoms to get tested, but those with symptoms will get priority.
A new study in NatureTrusted Source found that the virus that causes COVID-19 was detected in the air in certain areas of two hospitals.
The two hospitals in Wuhan, China are at the center of the outbreak in that country. Researchers found evidence of aerosolized SARS-CoV-2 in the toilet area and in areas prone to crowding.
The study has given more information about whether the virus is easily transmitted through the air. Researchers said proper ventilation and disinfection may help stop the virus from spreading in other similar areas.
The Food and Drug Administration (FDA) is expected to give emergency use authorization for the drug remdesivir to treat people with COVID-19.
The antiviral drug is being studied in multiple tests as a potential treatment for COVID-19. Early research has found that the drug may help people recover from the virus more quickly, according to the New York Times.
Dr. Anthony Fauci, director for the National Institute for Allergies and Infectious Diseases, told the New York Times that administering the drug to people with COVID-19 may shorten their recovery time by about a third.
“Although a 31 percent improvement doesn’t seem like a knockout 100 percent, it is a very important proof of concept because what it has proven is that a drug can block this virus,” Fauci said. “This is very optimistic.”
However, more research will need to be done to understand what — if any — long-term benefit there is to taking the drug.
Another study from the Lancet found no benefit for patients taking remdesivir compared to patients taking a placebo.